Isturisa
- Prescription status not stated
- Hormones, such as thyroid and steroids
- Active substance
- Osilodrostat
- Made by
- Recordati Rare Diseases
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (Isturisa). It describes the substance, not this exact product.
Osilodrostat is a cortisol synthesis inhibitor.
It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland.
In an absorption, distribution, metabolism, and excretion study, the majority of the radioactivity dose of osilodrostat is eliminated in the urine (mean: 90.6% of administered dose) with only a minor amount eliminated in the feces (1.58% of dose).
Effect of Food In a healthy volunteer study (N = 20), subjects administered with a single, 30 mg oral dose of ISTURISA film-coated tablets with a high-fat meal resulted in reduction of AUC by 11% and C max by 21%, respectively.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-18
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Recordati Rare Diseases |
|---|---|
| Active substance | Osilodrostat |
| Used in | Hormones, such as thyroid and steroids |
| Classification | H02CA02 · Hormones, such as thyroid and steroids |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2020-01-09 |
| Last updated by the regulator | 2024-12-12 |
| EMA product number | EMEA/H/C/004821 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).